Vascular Biogenics Ltd. VBLT
0.16 -0.02 (-8.77%)
At closeOct 16, 2023, 4:00 PM EDT
0.1526 Day range 0.1925
0.1009 52-week range 0.32
- Market cap
- 12.11M
- Revenue (ttm)
- 481.00K
- EPS (ttm)
- -0.18
- Shares out
- 77.64M
- P/E ratio
- -0.87
- Forward P/E
- -0.26
- Volume
- 5.38M
- Avg volume
- 787.72K
- Open
- 0.1734
- Previous close
- 0.171
- Day's range
- 0.1526 – 0.1925
- 52-week range
- 0.1009 – 0.32
- Beta
- 0.71
- Analysts
- Hold
- Earnings date
- Nov 13, 2023
No chart data for this range yet.
Key statistics
- Enterprise value
- -10.99M
- PEG ratio
- 0.00
- Price / sales
- 25.18
- Price / book
- 0.57
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -10.84M
- Total cash
- 24.26M
- Total debt
- 0
- Return on equity
- -59.52%
- Short % of float
- 0.33%
- 50-day average
- 0.228423
- 200-day average
- 0.206284
Analyst view
Consensus: hold
Hold
Price target (mean) —
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy0
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 13, 2023
Expected Nov 13, 2023. Consensus EPS estimate 0.00.
Financials — quick view
VBLT Revenue — quarterly 0
VBLT Net income — quarterly -874.00K
VBLT EPS — quarterly 0.01
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| Mar 14, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | -0.11 | — | — | — |
| Aug 15, 2022 | Jun 1, 2022 | -0.13 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 20, 2022 | Chardan Capital | down | Buy | Neutral |
| Jul 19, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Apr 27, 2022 | Chardan Capital | init | — | Buy |
| Jun 2, 2021 | Roth Capital | main | — | Buy |
| Jan 27, 2021 | HC Wainwright & Co. | main | — | Buy |
| Apr 16, 2020 | Oppenheimer | main | — | Outperform |
About Vascular Biogenics Ltd.
Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- vblrx.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on VBLT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BACKENROTH SAMUEL | Chief Financial Officer | Conversion of Exercise of derivative security | Mar 30, 2023 | 525,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Telemetry Investments, L.L.C. | 0.57% | 403,500 | 48.42K | Dec 30, 2022 |
| Morgan Stanley | 0.46% | 327,011 | 75.21K | Jun 29, 2023 |
| Group One Trading, L.P. | 0.18% | 127,293 | 29.28K | Jun 29, 2023 |
| Virtu Financial LLC | 0.11% | 79,892 | 18.38K | Jun 29, 2023 |
| Catalyst Financial Partners LLC | 0.06% | 39,000 | 8.97K | Jun 29, 2023 |
| Geode Capital Management, LLC | 0.06% | 40,323 | 9.27K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.06% | 40,323 | 8.46K | May 30, 2023 |